Advertisement

Somatostatin pp 251-270 | Cite as

Somatostatin Analogue Therapy of Neuro-Endocrine Gastro-Entero Pancreatic Tumors

  • Kjell Öberg
Part of the Endocrine Updates book series (ENDO, volume 24)

Keywords

Neuroendocrine GEP-tumors carcinoids somatostatin analogue somatostatin receptors octreotide lanreotide combination therapy acromegaly prolactinomas Cushing’s disease clinically nonfunctioning adenomas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Angeletti, S., Corleto, V.D., and Schiallachi, O. (1998). Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42, 792–794.PubMedGoogle Scholar
  2. 2.
    Anthony, L., Johnson, D., and Hande, K. (1993). Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32, 217–223.PubMedGoogle Scholar
  3. 3.
    Anthony, L.B., Skyr, Y., Wim, S.D., and Oates, J.A. (1996). Octreotide acelate (OA) in the management of malignant carcinoid syndrome (CS). Ann Oncol 7(suppl 5), 47 (abs 219P).Google Scholar
  4. 4.
    Arnold, R., Trautmann, M.E., and Creutzfeldt, W. (1996). Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38, 430–438.PubMedGoogle Scholar
  5. 5.
    Bauer, W., Briner, U., and Doepfner W. (1982). A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31, 1133–1140.CrossRefPubMedGoogle Scholar
  6. 6.
    Bergström, M., Eriksson, B., and Öberg K. (1996). In vivo demonstration of enzyme activity in endocrine pancreatic tumors-decarboxylation of 11C-dopa to 11C-dopamine. J Nucl med 36, 32–37.Google Scholar
  7. 7.
    Buscail, L., Esteve, J.P., and Saint-Laurent, N. (1995). Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci 92, 1580–1584.PubMedGoogle Scholar
  8. 8.
    Carrasco, C.H., Chuang, V., and Wallace, S. (1983). Apudoma metastatic to the liver: Treatment by hepatic artery embolization. Radiology 149, 79–83.PubMedGoogle Scholar
  9. 9.
    Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., and the ITMO Association (1996). Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 77, 402–408.PubMedGoogle Scholar
  10. 10.
    Eckhauser, F.E., Cheung, P.S., and Vinik, A.I. (1986). Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 100, 978.PubMedGoogle Scholar
  11. 11.
    Eriksson, B., Arnberg, H., and Lindgren, P.G. (1990). Neuroendocrine pancreatic tumors: Clinical presentation, biochemical and histopathological tumors: Clinical presentation, biochemical and histopathological findings in 84 patients. J Int Med 228, 103–113.Google Scholar
  12. 12.
    Eriksson, B., Janson ET, and Bax, N.D.S. (1996). The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors. Digestion 57, 77–80.PubMedGoogle Scholar
  13. 13.
    Eriksson, B., Renstrup, J., Imam, H., and Öberg, K. (1997). High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 8, 1041–1044.CrossRefPubMedGoogle Scholar
  14. 14.
    Eriksson, B., and Öberg, K. (1999). Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors. Future outlook. Ann Oncol 10(Suppl 2), S1–8.Google Scholar
  15. 15.
    Faiss, S., and Wiedenmann, B. (1997). Dose-dependent and antiprolifcrativc effects of somatostatin. J Endocrinol Invest 20, 68–70.Google Scholar
  16. 16.
    Fajans, S.S., and Vinik, A.I. (1989). Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 18, 45.PubMedGoogle Scholar
  17. 17.
    Feldman, J.M. (1987). Carcinoid tumors and syndrome. Semin Oncol 14, 237.PubMedGoogle Scholar
  18. 18.
    Frank, M., Klose, K.J., Wied, M., Ishaque, N., Schade-Brittinger C., and Arnold, R. (1999). Combination therapy with octreotide and α-interferon: Effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94, 1382–1387.Google Scholar
  19. 19.
    Fröhlich, J.C., Bloomgarden, Z.T., and Oates, J.A. (1978). The carcinoid flush: Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299, 1055–1057.Google Scholar
  20. 20.
    Gorden, P., Comi, R.J., Maton, P.N., and Go V.L.W. (1989). Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110, 35–50.PubMedGoogle Scholar
  21. 21.
    Harris, A., Kokoris, S., and Ezzat, S. (1995). Continuous versus intermittent sub-cutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol 35, 59–71.PubMedGoogle Scholar
  22. 22.
    Harris, A., and Redfern, J.S. (1995). Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data. Aliment of published dose-titration data. Aliment Pharmacol Ther 9, 387–394.PubMedGoogle Scholar
  23. 23.
    Heron, I., Thomas, F., and Dero, M. (1993). Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BlM-23014 in patients with acromegaly. J clin Endocrinol Metabol 76, 721–727.CrossRefGoogle Scholar
  24. 24.
    Hoefnagel, C.A., den Hartog Jager, F.C., and Taal, E.G. (1987). The role of 125I-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13, 187.CrossRefPubMedGoogle Scholar
  25. 25.
    Hofland, L.J., Koelsveld, and Waaijers, M. (1994). Relative potencies of the somato-statin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultures human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinol 134, 301–306.CrossRefGoogle Scholar
  26. 26.
    Imam, H., Eriksson, B., and Lukinius A. (1997). Induction of apoptosis in neuro-endocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 36, 607–614.PubMedGoogle Scholar
  27. 27.
    Janson, E.T., Ahlström, H., Andersson, T., and Öberg, K (1992). Octreotide and interferon-α: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 28A, 1647–1650.Google Scholar
  28. 28.
    Jensen, R.T. (1983). Zollinger-Ellison syndrome: Current concepts and management. Ann Int Med 98, 59–75.PubMedGoogle Scholar
  29. 29.
    Jockenhovel, S., Lederbogen S., and Olbricht, T. (1994). The long-acting somatostatin analogue: Symptomatic and peptide response. Gut 26, 127–133.Google Scholar
  30. 30.
    Joensuu, H., Kätkä, K. and Kujari, H. (1992). Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 126, 184–185.Google Scholar
  31. 31.
    Krejs, G.J., Ocri, L., and Conlon, M. (1979). Somatostatinoma syndrome (biochemical, morphological, and clinical features). N Engl J Med 301, 285.PubMedGoogle Scholar
  32. 32.
    Krenning, E.P., Kwekkeboom, D.J., and Bakker, W.H. (1993). Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1) and (123Tyr3)-octreotide. The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20, 716–731.CrossRefPubMedGoogle Scholar
  33. 33.
    Kvols, L.K., Marsh, H.M., and Moertel, C.G. (1985). Rapid reversal of carcinoid crisis with a somatostatin analouge. N Engl J Med 313, 1229–1230.PubMedGoogle Scholar
  34. 34.
    Kvols, L.K., Moertel, C.G., and O’Connell M.J. (1986). Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315, 663–666.PubMedGoogle Scholar
  35. 35.
    Kvols, L.K., and Reubi, J.C. (1993). Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 32:2, 197–201.PubMedGoogle Scholar
  36. 36.
    Lamberts, S.W.J., Krenning, E.P., and Reubi, J.C. (1991). The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 12, 450–482.Google Scholar
  37. 37.
    Lancranjan, I., Brims, C., and Grass, P. (1995). Sandostatin-LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 44, 18–26.CrossRefGoogle Scholar
  38. 38.
    Larsson, C., Skogseid B., and Öberg, K. (1988). Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332, 85–87.CrossRefPubMedGoogle Scholar
  39. 39.
    Long, R.G., Bryant, M.G., and Mitchell, S.J. (1981). Clinicopathological study of pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestinal polypeptide (VIPomas). Br J Med J 282, 1767.Google Scholar
  40. 40.
    Makridis, C., Öberg, K., and Juhlin, C. (1990). Surgical tretment of midgut carcinoid tumors. World J Surg 14, 377.CrossRefPubMedGoogle Scholar
  41. 41.
    Maton, P.N., Gardner, J.D., and Jensen, R.T. (1989). Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34, 285–291.CrossRefGoogle Scholar
  42. 42.
    Moertel, C.G., Johnson, C.M., and McKusick, M.A. (1994). The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 120, 302–309.PubMedGoogle Scholar
  43. 43.
    Nagy, A., Schally, A.V., Halmos, G., Armatis, P., Cai, R.Z., and Csernus, V. (1986). Synthesis and biological evaluation of cytotoxic analogues of somatostatin containing doxorubicin and its potent derivative 2-pyrrolinodoxorubicin. Br J Surg 83, 456–460.Google Scholar
  44. 44.
    Norheim, I., Öberg, K., and Theodorsson-Norheim, E. (1987). Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206, 115–125.PubMedGoogle Scholar
  45. 45.
    Otte, A., Mueller-brand, J., and Dellas, S. (1998), Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 351, 417–418.CrossRefPubMedGoogle Scholar
  46. 46.
    Patel, Y.C. (1999). Somatostatin and its receptor family. Frontiers in Neuroendo-crinology 20, 157–198.Google Scholar
  47. 47.
    Radulovic, S., Nagy, A., Szoke, B., and Schally, A. (1992). Cytotoxic analogue of somatostatin containing methotrexate inhibits growth of MIA PaCA-2 human pancreatic xenografts in nude mice. Cancer lett 62, 263–271.CrossRefPubMedGoogle Scholar
  48. 48.
    Reubi, J.C., Kvols, L.K., and Waser, B. (1990). Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples and islet cell carcinomas. Cancer Res 50, 5969–5977.PubMedGoogle Scholar
  49. 49.
    Ricci, S., Anonuzzo, A., Galli, L., Ferdeghini, M., Bodei, L., Orlandini, C., and Conte, P.F. (2000). Octreotide acelate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotidc. Ann Oncol 11, 1127–1130.CrossRefPubMedGoogle Scholar
  50. 50.
    Rindi, G., Luinetti, O., and Cornaggia, M. (1993). Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma. A Clinicopathological study. Gastroenterol 104, 994–1006.Google Scholar
  51. 51.
    Rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., and Patel, Y.C., (2000). Receptors for dopamine and somatostatin: Formalin of hetero-oligomers with enhanced functional activity. Science 288, 154–157.CrossRefPubMedGoogle Scholar
  52. 52.
    Rubin, J., Ajani, J., Schinner, W., Wenok, A.P., Bukowski, R., Pommier, R., Salz, L., Danona, P., and Anthony, L. (1999). Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17, 600–606.PubMedGoogle Scholar
  53. 53.
    Ruszniewski, P., Ramdani, A., and Cadiot G. (1993). Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Fur J Clin Invest 23, 296–301.Google Scholar
  54. 54.
    Ruszniewski, P., Ducreux, M., and Chay vialle, J.A. (1996). Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide. A prospective study in 39 patients. Gut 39, 279–283.PubMedGoogle Scholar
  55. 55.
    Saltz, L., Trochanowski, B., and Buckley, M. (1993). Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72, 244–248.PubMedGoogle Scholar
  56. 56.
    Scarpignato, C. (1995). Somatostatin analogues in the management of endocrine tumors of the pancreas. In Mignon M, Jensen RT (eds): Endocrine Tumors of the Pancreas. Basel: Karger, 385–414.Google Scholar
  57. 57.
    Scarpignato, C., and Pelosini, I. (2001). Somatostatin analogs for cancer treatment and diagnosis-an overview; In: Somatostatin Analogs in Cancer Management. Ed. C. Scarpignato (Karger). Chemotherapy 47(Suppl 2), 1–29.Google Scholar
  58. 58.
    Scherübl, H., Wiedenmann, B. and Riecken, E.O. (1994). Treatment of the carcinoid syndrome with a depot formulation of the Somatostatin analogue lanreotide. Eur J Cancer 6, 1590–1591.Google Scholar
  59. 59.
    Sharma, K., Patel, X.C., and Srikant, C.B. (1996). Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human Somatostatin receptor 3. Mol Endocrinol 10, 1688–1696.CrossRefPubMedGoogle Scholar
  60. 60.
    Shi, W., Buchanan, K.D., Johnston, C.F., Larkin, C., Ong, Y.L., Ferguson, R., and Laird, J. (1998). The octreotide suppression test and (111In-DTPA-D-Ph1)-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to Somatostatin analogue treatment. Clin Endocrinol 48, 303–309.CrossRefGoogle Scholar
  61. 61.
    Shimon, I., Taylor, J., and Weiss, M.H. (1997). Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J clin Invest 100, 2386–2392.PubMedGoogle Scholar
  62. 62.
    Skogseid, B., Eriksson, B., and Lundqvist, G. (1991). Multiple endocrine neoplasia type 1: A ten-year preospective screening study in four kindreds. J Clin Endocrinol Metab 73, 281–287.PubMedGoogle Scholar
  63. 63.
    Spread, C., Berkel, H., and Jewell L. (1994). Colon carcinoid tumors. A population-based study. Dis Colon Rectum 37, 482–491.CrossRefPubMedGoogle Scholar
  64. 64.
    Stacpoole, P.W. (1981). The glucagonoma syndrome: Clinical features, diagnosis, and treatment, endocr Rev 2, 347.Google Scholar
  65. 65.
    Taylor, J.E., Bogden, A.E., Moreau, J.P., and Coy D.H. (1988). In vitro inhibition of human small-cell carcinoma (NCL-H69) growth by Somatostatin analogue. Biochem Biophys Res Commun 153, 81–86.CrossRefPubMedGoogle Scholar
  66. 66.
    Tiensuu Janson, E., Westlin, J.E., and Eriksson, B. (1994). (111In-DTPA-D-Phe1)-Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for Somatostatin analog treatment. Eur J Endocrinol 131, 577–581.Google Scholar
  67. 67.
    Trendle, M.C., Moertel, C.G., and Kvols, L.K. (1997). Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumours. Cancer 79, 830–834.CrossRefPubMedGoogle Scholar
  68. 68.
    Thulin, L., Samnegård, H., and Tyden, G. (1978). Efficacy of Somatostatin in a patient with carcinoid syndrome. Lancet 2, 43.PubMedGoogle Scholar
  69. 69.
    Weckbecker, G., Liu, R., Tolcsvai, L., and Bruns, C. (1992). Antiproliferative effectsof the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52, 4973–4978.PubMedGoogle Scholar
  70. 70.
    Wilander, E., Lundqvist, M., and Öberg, K. (1989). Gastrointestinal carcinoid tumours. Prog Histochem Cytochem 19, 1–85.PubMedGoogle Scholar
  71. 71.
    Williams, E.D., and Sandler, M. (1963). The classification of carcinoid tumours. The Lancet 1, 238–239.Google Scholar
  72. 72.
    Woltering, E.A., Watson, J.C., Alperin-Lea, C, Sharma, C., Keenan, E., Kurdzawa, D.L., and Barrie, R. (1997). Somatostatin analogues: Angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15, 77–86.CrossRefPubMedGoogle Scholar
  73. 73.
    Wood S.M., Kraenzlin, M.E., Adrian, T.E., and Bloom, S.R (1985) Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide response. Gut 26, 438–444.PubMedGoogle Scholar
  74. 74.
    Wymenga, A.N.M., Eriksson, B., and Salmela, P.I. (1999). Efficacy and safety of lanreotide prolonged release in patients with gastrointestinal neuro-endocrine tumors with hormone related symptoms. J Clin Oncol 4, 1111–1117.Google Scholar
  75. 75.
    Wynick, D., Andersson, J.V., Williams, S.J., and Bloom, S.R. (1989). Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30, 385–388.Google Scholar
  76. 76.
    Öberg, K., Norheim, I., Lundqvist, G., and Wide, L. (1986). Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analouge. Scand J Gastroenterol 119, 191–192.Google Scholar
  77. 77.
    Öberg, K., and Eriksson, B. (1991). The role of interferons in the management of carcinoid tumors. Acta Oncol 30, 519–522.PubMedGoogle Scholar
  78. 78.
    Öberg, K. (1996). Neuroendocrine tumors. Ann Oncol 7, 453–463.PubMedGoogle Scholar
  79. 79.
    Öberg, K. (2001). Established clinical use of octreotide and lancreotide in oncology. Chemotherapy 47,(suppl 2), 40–53.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2004

Authors and Affiliations

  • Kjell Öberg
    • 1
  1. 1.Department of MedicineUppsala University HospitalUppsalaSweden

Personalised recommendations